Tocotrienol: a review of its therapeutic potential
Related Experiment Video
Updated: Oct 19, 2026

Formulation of Vitamin A Tracer Doses for Administration to Human Subjects using Retinol Isotope Dilution Technique
Published on: March 31, 2026
A Theriault1, J T Chao, Q Wang
1Division of Medical Technology, University of Hawaii at Manoa, Honolulu 96822, USA. andret@hawaii.edu
Objectives:
To summarize new knowledge surrounding the physiological activity of tocotrienol, a natural analogue of tocopherol.
Results:
The biological activity of vitamin E has generally been associated with its well-defined antioxidant property, specifically against lipid peroxidation in biological membranes. In the vitamin E group, alpha-tocopherol is considered to be the most active form. However, recent research has suggested tocotrienol to be a better antioxidant. Moreover, tocotrienol has been shown to possess novel hypocholesterolemic effects together with an ability to reduce the atherogenic apolipoprotein B and lipoprotein(a) plasma levels. In addition, tocotrienol has been suggested to have an anti-thrombotic and anti-tumor effect indicating that tocotrienol may serve as an effective agent in the prevention and/or treatment of cardiovascular disease and cancer.
Conclusion:
The physiological activities of tocotrienol suggest it to be superior than alpha-tocopherol in many situations. Hence, the role of tocotrienol in the prevention of cardiovascular disease and cancer may have significant clinical implications. Additional studies on its mechanism of action, as well as, long-term intervention studies, are needed to clarify its function. From the pharmacological point-of-view, the current formulation of vitamin E supplements, which is comprised mainly of alpha-tocopherol, may be questionable.
Related Concept Videos
Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring: Affecting Factors
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Therapeutic Index
Atherosclerosis III: Management
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence